Author Interviews, Cancer Research, JAMA / 07.09.2017

MedicalResearch.com Interview with: Elias Jabbour, MD Associate Professor Leukemia Department MD Anderson Cancer Center MedicalResearch.com: What is the background for this study? What are the main findings? Response: Inotuzumab is active in relapsed or refractory (R/R) acute lymphoblastic leukemia ¬†(R/R ALL). The addition of low intensity chemotherapy may further improve outcome. ORR around 80%. Median survival 11 months. Better results obtained in Savage 1. Superior outcome when compared to historical cohort treated with inotuzumab monotherapy (more…)
Author Interviews, Chemotherapy, Melanoma, Radiation Therapy / 24.05.2016

MedicalResearch.com Interview with: James S. Welsh, MS, MD, FACRO President,¬†American College of Radiation Oncology Professor and Medical Director Director of Clinical & Translational Research Department of Radiation Oncology Stritch School of Medicine Loyola University- Chicago Cardinal Bernardin Cancer Center Maywood, IL 60153 Chief of Radiation Oncology Hines VA Medical Center MedicalResearch.com: What is the background for this study? What are the main findings? Dr. Welsh: Cancer immunotherapy could represent a truly powerful means of addressing cancer. Although immunotherapy itself is not new, there are new agents and combinations of older agents (including radiation therapy) that could prove more successful than anything we have seen in many years. The data in melanoma thus far is quite encouraging and this preliminary success could possibly extend to many other malignancies as well. (more…)